Trial Profile
A Single-Center, Open-Label Study Evaluating the Efficacy of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Lowering Intraocular Pressure Over a 24-Hour Period in Japanese Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Nov 2015
Price :
$35
*
At a glance
- Drugs Latanoprostene bunod (Primary)
- Indications Ocular hypertension
- Focus Pharmacodynamics
- Acronyms KRONUS
- Sponsors Bausch & Lomb
- 12 Nov 2015 Results published in the Advances in Therapy
- 15 May 2014 According to the Nicox media release, results of this trial were presented at Association for Research in Vision and Ophthalmology (ARVO) Annual meeting in Orlando, Florida on May 4-8 2014.
- 06 Dec 2013 New trial record